Novartis: Faces A Tougher Test As Patent Losses And Pipeline Setbacks Mount (NYSE:NVS)
· seekingalpha.com
Novartis reported 2Q26 revenue of $14.4 billion, as strong demand for newer medicines was largely offset by generic competition. See why NVS stock is a Hold.
I am an Investment Research Analyst with a strong interest in fundamental equity research, valuation, and long-term investing, with a primary focus on the U.S. ...